Service & Software

Global Pediatric CAR T-cell Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031

Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Pediatric CAR T-cell Therapy market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Bristol Myers Squibb，BMS
Johnson & Johnson
Gilead Sciences
Novartis
JW Therapeutics
Imunopharm Technology Co., Ltd.
CARsgen Therapeutics
Cartesian Therapeutics
Segment by Type
CD19
BCMA
Others
Segment by Application
Multiple Myeloma
B-Cell Lymphoma (BCL)
Acute Lymphoblastic Leukemia (ALL)
Others
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Pediatric CAR T-cell Therapy study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Pediatric CAR T-cell Therapy: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Pediatric CAR T-cell Therapy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 CD19
1.2.3 BCMA
1.2.4 Others
1.3 Market Segmentation by Application
1.3.1 Global Pediatric CAR T-cell Therapy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Multiple Myeloma
1.3.3 B-Cell Lymphoma (BCL)
1.3.4 Acute Lymphoblastic Leukemia (ALL)
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Pediatric CAR T-cell Therapy Revenue Estimates and Forecasts 2020-2031
2.2 Global Pediatric CAR T-cell Therapy Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Pediatric CAR T-cell Therapy Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Pediatric CAR T-cell Therapy Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 CD19 Market Size by Players
3.3.2 BCMA Market Size by Players
3.3.3 Others Market Size by Players
3.4 Global Pediatric CAR T-cell Therapy Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Pediatric CAR T-cell Therapy Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Pediatric CAR T-cell Therapy Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Pediatric CAR T-cell Therapy Market Size by Type (2020-2031)
6.4 North America Pediatric CAR T-cell Therapy Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Pediatric CAR T-cell Therapy Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Pediatric CAR T-cell Therapy Market Size by Type (2020-2031)
7.4 Europe Pediatric CAR T-cell Therapy Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Pediatric CAR T-cell Therapy Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Pediatric CAR T-cell Therapy Market Size by Type (2020-2031)
8.4 Asia-Pacific Pediatric CAR T-cell Therapy Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Pediatric CAR T-cell Therapy Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Pediatric CAR T-cell Therapy Market Size by Type (2020-2031)
9.4 Central and South America Pediatric CAR T-cell Therapy Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Pediatric CAR T-cell Therapy Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Pediatric CAR T-cell Therapy Market Size by Type (2020-2031)
10.4 Middle East and Africa Pediatric CAR T-cell Therapy Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Pediatric CAR T-cell Therapy Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Bristol Myers Squibb，BMS
11.1.1 Bristol Myers Squibb，BMS Corporation Information
11.1.2 Bristol Myers Squibb，BMS Business Overview
11.1.3 Bristol Myers Squibb，BMS Pediatric CAR T-cell Therapy Product Features and Attributes
11.1.4 Bristol Myers Squibb，BMS Pediatric CAR T-cell Therapy Revenue and Gross Margin (2020-2025)
11.1.5 Bristol Myers Squibb，BMS Pediatric CAR T-cell Therapy Revenue by Product in 2024
11.1.6 Bristol Myers Squibb，BMS Pediatric CAR T-cell Therapy Revenue by Application in 2024
11.1.7 Bristol Myers Squibb，BMS Pediatric CAR T-cell Therapy Revenue by Geographic Area in 2024
11.1.8 Bristol Myers Squibb，BMS Pediatric CAR T-cell Therapy SWOT Analysis
11.1.9 Bristol Myers Squibb，BMS Recent Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Corporation Information
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Pediatric CAR T-cell Therapy Product Features and Attributes
11.2.4 Johnson & Johnson Pediatric CAR T-cell Therapy Revenue and Gross Margin (2020-2025)
11.2.5 Johnson & Johnson Pediatric CAR T-cell Therapy Revenue by Product in 2024
11.2.6 Johnson & Johnson Pediatric CAR T-cell Therapy Revenue by Application in 2024
11.2.7 Johnson & Johnson Pediatric CAR T-cell Therapy Revenue by Geographic Area in 2024
11.2.8 Johnson & Johnson Pediatric CAR T-cell Therapy SWOT Analysis
11.2.9 Johnson & Johnson Recent Developments
11.3 Gilead Sciences
11.3.1 Gilead Sciences Corporation Information
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Pediatric CAR T-cell Therapy Product Features and Attributes
11.3.4 Gilead Sciences Pediatric CAR T-cell Therapy Revenue and Gross Margin (2020-2025)
11.3.5 Gilead Sciences Pediatric CAR T-cell Therapy Revenue by Product in 2024
11.3.6 Gilead Sciences Pediatric CAR T-cell Therapy Revenue by Application in 2024
11.3.7 Gilead Sciences Pediatric CAR T-cell Therapy Revenue by Geographic Area in 2024
11.3.8 Gilead Sciences Pediatric CAR T-cell Therapy SWOT Analysis
11.3.9 Gilead Sciences Recent Developments
11.4 Novartis
11.4.1 Novartis Corporation Information
11.4.2 Novartis Business Overview
11.4.3 Novartis Pediatric CAR T-cell Therapy Product Features and Attributes
11.4.4 Novartis Pediatric CAR T-cell Therapy Revenue and Gross Margin (2020-2025)
11.4.5 Novartis Pediatric CAR T-cell Therapy Revenue by Product in 2024
11.4.6 Novartis Pediatric CAR T-cell Therapy Revenue by Application in 2024
11.4.7 Novartis Pediatric CAR T-cell Therapy Revenue by Geographic Area in 2024
11.4.8 Novartis Pediatric CAR T-cell Therapy SWOT Analysis
11.4.9 Novartis Recent Developments
11.5 JW Therapeutics
11.5.1 JW Therapeutics Corporation Information
11.5.2 JW Therapeutics Business Overview
11.5.3 JW Therapeutics Pediatric CAR T-cell Therapy Product Features and Attributes
11.5.4 JW Therapeutics Pediatric CAR T-cell Therapy Revenue and Gross Margin (2020-2025)
11.5.5 JW Therapeutics Pediatric CAR T-cell Therapy Revenue by Product in 2024
11.5.6 JW Therapeutics Pediatric CAR T-cell Therapy Revenue by Application in 2024
11.5.7 JW Therapeutics Pediatric CAR T-cell Therapy Revenue by Geographic Area in 2024
11.5.8 JW Therapeutics Pediatric CAR T-cell Therapy SWOT Analysis
11.5.9 JW Therapeutics Recent Developments
11.6 Imunopharm Technology Co., Ltd.
11.6.1 Imunopharm Technology Co., Ltd. Corporation Information
11.6.2 Imunopharm Technology Co., Ltd. Business Overview
11.6.3 Imunopharm Technology Co., Ltd. Pediatric CAR T-cell Therapy Product Features and Attributes
11.6.4 Imunopharm Technology Co., Ltd. Pediatric CAR T-cell Therapy Revenue and Gross Margin (2020-2025)
11.6.5 Imunopharm Technology Co., Ltd. Recent Developments
11.7 CARsgen Therapeutics
11.7.1 CARsgen Therapeutics Corporation Information
11.7.2 CARsgen Therapeutics Business Overview
11.7.3 CARsgen Therapeutics Pediatric CAR T-cell Therapy Product Features and Attributes
11.7.4 CARsgen Therapeutics Pediatric CAR T-cell Therapy Revenue and Gross Margin (2020-2025)
11.7.5 CARsgen Therapeutics Recent Developments
11.8 Cartesian Therapeutics
11.8.1 Cartesian Therapeutics Corporation Information
11.8.2 Cartesian Therapeutics Business Overview
11.8.3 Cartesian Therapeutics Pediatric CAR T-cell Therapy Product Features and Attributes
11.8.4 Cartesian Therapeutics Pediatric CAR T-cell Therapy Revenue and Gross Margin (2020-2025)
11.8.5 Cartesian Therapeutics Recent Developments
12 Pediatric CAR T-cell TherapyIndustry Chain Analysis
12.1 Pediatric CAR T-cell Therapy Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Pediatric CAR T-cell Therapy Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Pediatric CAR T-cell Therapy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Pediatric CAR T-cell Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Pediatric CAR T-cell Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Pediatric CAR T-cell Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Pediatric CAR T-cell Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Pediatric CAR T-cell Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Pediatric CAR T-cell Therapy Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Pediatric CAR T-cell Therapy Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Pediatric CAR T-cell Therapy by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pediatric CAR T-cell Therapy as of 2024)
Table 11. Global Pediatric CAR T-cell Therapy Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Pediatric CAR T-cell Therapy Companies Headquarters
Table 13. Global Pediatric CAR T-cell Therapy Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Pediatric CAR T-cell Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Pediatric CAR T-cell Therapy Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Pediatric CAR T-cell Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Pediatric CAR T-cell Therapy Revenue by Application (2026-2031) & (US$ Million)
Table 21. Pediatric CAR T-cell Therapy High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Pediatric CAR T-cell Therapy Growth Accelerators and Market Barriers
Table 25. North America Pediatric CAR T-cell Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Pediatric CAR T-cell Therapy Growth Accelerators and Market Barriers
Table 27. Europe Pediatric CAR T-cell Therapy Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Pediatric CAR T-cell Therapy Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Pediatric CAR T-cell Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Pediatric CAR T-cell Therapy Investment Opportunities and Key Challenges
Table 31. Central and South America Pediatric CAR T-cell Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Pediatric CAR T-cell Therapy Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Pediatric CAR T-cell Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Bristol Myers Squibb，BMS Corporation Information
Table 35. Bristol Myers Squibb，BMS Description and Major Businesses
Table 36. Bristol Myers Squibb，BMS Product Features and Attributes
Table 37. Bristol Myers Squibb，BMS Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Bristol Myers Squibb，BMS Revenue Proportion by Product in 2024
Table 39. Bristol Myers Squibb，BMS Revenue Proportion by Application in 2024
Table 40. Bristol Myers Squibb，BMS Revenue Proportion by Geographic Area in 2024
Table 41. Bristol Myers Squibb，BMS Pediatric CAR T-cell Therapy SWOT Analysis
Table 42. Bristol Myers Squibb，BMS Recent Developments
Table 43. Johnson & Johnson Corporation Information
Table 44. Johnson & Johnson Description and Major Businesses
Table 45. Johnson & Johnson Product Features and Attributes
Table 46. Johnson & Johnson Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Johnson & Johnson Revenue Proportion by Product in 2024
Table 48. Johnson & Johnson Revenue Proportion by Application in 2024
Table 49. Johnson & Johnson Revenue Proportion by Geographic Area in 2024
Table 50. Johnson & Johnson Pediatric CAR T-cell Therapy SWOT Analysis
Table 51. Johnson & Johnson Recent Developments
Table 52. Gilead Sciences Corporation Information
Table 53. Gilead Sciences Description and Major Businesses
Table 54. Gilead Sciences Product Features and Attributes
Table 55. Gilead Sciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Gilead Sciences Revenue Proportion by Product in 2024
Table 57. Gilead Sciences Revenue Proportion by Application in 2024
Table 58. Gilead Sciences Revenue Proportion by Geographic Area in 2024
Table 59. Gilead Sciences Pediatric CAR T-cell Therapy SWOT Analysis
Table 60. Gilead Sciences Recent Developments
Table 61. Novartis Corporation Information
Table 62. Novartis Description and Major Businesses
Table 63. Novartis Product Features and Attributes
Table 64. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Novartis Revenue Proportion by Product in 2024
Table 66. Novartis Revenue Proportion by Application in 2024
Table 67. Novartis Revenue Proportion by Geographic Area in 2024
Table 68. Novartis Pediatric CAR T-cell Therapy SWOT Analysis
Table 69. Novartis Recent Developments
Table 70. JW Therapeutics Corporation Information
Table 71. JW Therapeutics Description and Major Businesses
Table 72. JW Therapeutics Product Features and Attributes
Table 73. JW Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. JW Therapeutics Revenue Proportion by Product in 2024
Table 75. JW Therapeutics Revenue Proportion by Application in 2024
Table 76. JW Therapeutics Revenue Proportion by Geographic Area in 2024
Table 77. JW Therapeutics Pediatric CAR T-cell Therapy SWOT Analysis
Table 78. JW Therapeutics Recent Developments
Table 79. Imunopharm Technology Co., Ltd. Corporation Information
Table 80. Imunopharm Technology Co., Ltd. Description and Major Businesses
Table 81. Imunopharm Technology Co., Ltd. Product Features and Attributes
Table 82. Imunopharm Technology Co., Ltd. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Imunopharm Technology Co., Ltd. Recent Developments
Table 84. CARsgen Therapeutics Corporation Information
Table 85. CARsgen Therapeutics Description and Major Businesses
Table 86. CARsgen Therapeutics Product Features and Attributes
Table 87. CARsgen Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. CARsgen Therapeutics Recent Developments
Table 89. Cartesian Therapeutics Corporation Information
Table 90. Cartesian Therapeutics Description and Major Businesses
Table 91. Cartesian Therapeutics Product Features and Attributes
Table 92. Cartesian Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Cartesian Therapeutics Recent Developments
Table 94. Raw Materials Key Suppliers
Table 95. Distributors List
Table 96. Market Trends and Market Evolution
Table 97. Market Drivers and Opportunities
Table 98. Market Challenges, Risks, and Restraints
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources


List of Figures
Figure 1. Pediatric CAR T-cell Therapy Product Picture
Figure 2. Global Pediatric CAR T-cell Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. CD19 Product Picture
Figure 4. BCMA Product Picture
Figure 5. Others Product Picture
Figure 6. Global Pediatric CAR T-cell Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Multiple Myeloma
Figure 8. B-Cell Lymphoma (BCL)
Figure 9. Acute Lymphoblastic Leukemia (ALL)
Figure 10. Others
Figure 11. Pediatric CAR T-cell Therapy Report Years Considered
Figure 12. Global Pediatric CAR T-cell Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Pediatric CAR T-cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 14. Global Pediatric CAR T-cell Therapy Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Pediatric CAR T-cell Therapy Revenue Market Share by Region (2020-2031)
Figure 16. Global Pediatric CAR T-cell Therapy Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. CD19 Revenue Market Share by Player in 2024
Figure 19. BCMA Revenue Market Share by Player in 2024
Figure 20. Others Revenue Market Share by Player in 2024
Figure 21. Global Pediatric CAR T-cell Therapy Revenue Market Share by Type (2020-2031)
Figure 22. Global Pediatric CAR T-cell Therapy Revenue Market Share by Application (2020-2031)
Figure 23. North America Pediatric CAR T-cell Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 24. North America Top 5 Players Pediatric CAR T-cell Therapy Revenue (US$ Million) in 2024
Figure 25. North America Pediatric CAR T-cell Therapy Revenue (US$ Million) by Type (2020 - 2031)
Figure 26. North America Pediatric CAR T-cell Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 27. US Pediatric CAR T-cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 28. Canada Pediatric CAR T-cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 29. Mexico Pediatric CAR T-cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 30. Europe Pediatric CAR T-cell Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 31. Europe Top 5 Players Pediatric CAR T-cell Therapy Revenue (US$ Million) in 2024
Figure 32. Europe Pediatric CAR T-cell Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 33. Europe Pediatric CAR T-cell Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 34. Germany Pediatric CAR T-cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 35. France Pediatric CAR T-cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 36. U.K. Pediatric CAR T-cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 37. Italy Pediatric CAR T-cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 38. Russia Pediatric CAR T-cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Pediatric CAR T-cell Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Top 8 Players Pediatric CAR T-cell Therapy Revenue (US$ Million) in 2024
Figure 41. Asia-Pacific Pediatric CAR T-cell Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 42. Asia-Pacific Pediatric CAR T-cell Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 43. Indonesia Pediatric CAR T-cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 44. Japan Pediatric CAR T-cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 45. South Korea Pediatric CAR T-cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 46. Australia Pediatric CAR T-cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 47. India Pediatric CAR T-cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 48. Indonesia Pediatric CAR T-cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 49. Vietnam Pediatric CAR T-cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 50. Malaysia Pediatric CAR T-cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 51. Philippines Pediatric CAR T-cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 52. Singapore Pediatric CAR T-cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 53. Central and South America Pediatric CAR T-cell Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 54. Central and South America Top 5 Players Pediatric CAR T-cell Therapy Revenue (US$ Million) in 2024
Figure 55. Central and South America Pediatric CAR T-cell Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 56. Central and South America Pediatric CAR T-cell Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 57. Brazil Pediatric CAR T-cell Therapy Revenue (2020-2025) & (US$ Million)
Figure 58. Argentina Pediatric CAR T-cell Therapy Revenue (2020-2025) & (US$ Million)
Figure 59. Middle East and Africa Pediatric CAR T-cell Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 60. Middle East and Africa Top 5 Players Pediatric CAR T-cell Therapy Revenue (US$ Million) in 2024
Figure 61. South America Pediatric CAR T-cell Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 62. Middle East and Africa Pediatric CAR T-cell Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 63. GCC Countries Pediatric CAR T-cell Therapy Revenue (2020-2025) & (US$ Million)
Figure 64. Israel Pediatric CAR T-cell Therapy Revenue (2020-2025) & (US$ Million)
Figure 65. Egypt Pediatric CAR T-cell Therapy Revenue (2020-2025) & (US$ Million)
Figure 66. South Africa Pediatric CAR T-cell Therapy Revenue (2020-2025) & (US$ Million)
Figure 67. Pediatric CAR T-cell Therapy Industry Chain Mapping
Figure 68. Channels of Distribution (Direct Vs Distribution)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies